Protagonist Therapeutics (PTGX) Interest & Investment Income (2015 - 2026)

Protagonist Therapeutics has disclosed Interest & Investment Income across 12 years of filings, most recently posting $5.9 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $5.9 million, down 22.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.1 million (down 8.2% YoY), and the FY2025 annual result was $28.8 million, up 9.4% from the prior year.
• Interest & Investment Income came in at $5.9 million for Q1 2026 at Protagonist Therapeutics, down from $6.8 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $7.7 million in Q3 2024 to a low of $168000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $4.4 million (2024), against an average of $4.7 million.
• Across the five-year window, Interest & Investment Income jumped 1745.08% in 2022 and declined 22.41% in 2026, its largest moves.
• Protagonist Therapeutics' Interest & Investment Income stood at $2.3 million in 2022, then soared by 88.45% to $4.2 million in 2023, then surged by 61.55% to $6.9 million in 2024, then slipped by 1.34% to $6.8 million in 2025, then declined by 13.09% to $5.9 million in 2026.
• The last three Interest & Investment Income figures came in at $5.9 million (Q1 2026), $6.8 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.